CorWave develops innovative implantable cardiac pumps based on a breakthrough technology: the undulating membrane.
The CorWave corrugated membrane offers a novel approach in cardiac assist to provide true pulsatile blood flow.
CorWave is a fast-growing medical device company that develops novel cardiac assist pumps to provide reliable and sustainable solution to the major public health issue ofheart failure. The solutions developed by CorWave, which are truly physiological, will ensure better life to patients.
Founded in 2011 by the incubator MD Start and supported by renowned investors, CorWave has obtained over €35 million in funding and employs more than 50 employees.
CorWave has won numerous awards and competitions. In 2016 CorWave won phase 1 of the Global Innovation Contest (GIC) for the NovaPulse project. In 2017, this project also won phase 2 of the CMI competition. The same year, CorWave received the Deloitte Technology Fast 50 Biotech of the Future award, and in 2018 received support for the Calypso programme under the Programme d'Investissements d'Avenir (PIA) operated by Bpifrance.
News and press review :
L'USINE NOUVELLE / 14 APR 2018 / CorWave develops innovative cardiac assist technology
LA TRIBUNE / 14 MAY 2019 / Public Choice Award 2018, CorWave accelerates towards clinical trials
CHALLENGES / 08 NOV 2016 / CorWave, an exciting fundraising